VolitionRx's Innovative Contributions to Lung Cancer Research
VolitionRx Limited (NYSE AMERICAN: VNRX) stands at the forefront of groundbreaking studies that potentially transform the landscape of lung cancer diagnosis. At the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025, the company will present two significant posters that highlight their pioneering developments in cancer biomarkers and immunoassays. These advancements promise to improve prognostic evaluations and support treatment decisions in patients diagnosed with Non-Small Cell Lung Cancer (NSCLC).
Key Findings on Nu.Q® H3K27Me3 Biomarker
The first poster presentation centers on Volition's Nu.Q® H3K27Me3 biomarker. This particular biomarker, when used in conjunction with circulating tumor DNA (ctDNA), shows promise in enhancing overall survival projections. The results offer critical insights into how combining these technologies might lead to more informed treatment options for NSCLC patients.
Improving Patient Outcomes
By integrating the Nu.Q® H3K27Me3 biomarker into standard diagnostics, physicians may gain a better understanding of patient prognoses. This enhanced insight is essential for developing tailored treatment approaches that align closely with individual patient needs, potentially leading to improved outcomes.
Early Cancer Detection with Nu.Q® H3.1 Immunoassay
The second poster details the Nu.Q® H3.1 immunoassay, a cost-effective tool for early cancer detection. This innovative test can identify individuals at high risk for developing cancer, allowing for timely interventions. It represents a significant step forward in the quest for early cancer detection, which is often critical for successful treatment and management.
Cost-Efficient and Accessible Testing
One of the standout features of the Nu.Q® H3.1 test is its affordability, making it accessible to a wider population. This inclusivity helps ensure that more patients can benefit from early detection, thereby improving the overall quality of cancer care. With the ability to identify high-risk patients effectively, healthcare providers can implement preventive strategies earlier in the disease course.
Details of the Poster Sessions at ELCC 2025
Clinicians and researchers attending ELCC 2025, which will be held from March 26-29, 2025, in Paris, will have the opportunity to visit Volition's poster sessions. The first poster, designated as #282P, focuses on the early detection strategies for lung cancer. It will feature Jake Micallef, PhD, MBA, serving as the presenter for this vital study.
The second poster, #395P, will delve into the potential of the H3K27Me3 biomarker as a prognostic tool. This session will be led by Marie Piecyk, PhD, from the Center for Innovation in Cancerology of Lyon.
Volition's Commitment to Advancing Epigenetics
VolitionRx is dedicated to transforming the field of medical diagnostics by leveraging the power of epigenetics. The company aims to enhance early detection strategies for various diseases, including cancers and conditions associated with NETosis, such as sepsis. By providing simple and cost-effective blood tests, VolitionRx aims to improve the diagnosis and monitoring of serious health issues.
The company's research facilities are strategically located across various regions, including Belgium and the United States, supporting their mission of improving patient care globally.
About VolitionRx Limited
VolitionRx Limited is committed to advancing epigenetic science. With an emphasis on earlier disease detection and treatment monitoring, VolitionRx seeks to enhance outcomes for individuals suffering from life-threatening conditions. Their innovative approach includes the development of easy-to-use blood tests that can make a significant difference in both lives and healthcare.
Frequently Asked Questions
What is VolitionRx known for?
VolitionRx is recognized for its innovative biomarkers and immunoassay technologies aimed at improving cancer diagnosis and treatment.
What are the benefits of the Nu.Q® H3.1 immunoassay?
This immunoassay offers a cost-effective method for early cancer detection, allowing for timely interventions and better outcomes.
Where will the poster sessions take place?
The poster sessions will take place at the ESMO's European Lung Cancer Congress 2025 in Paris, showcasing cutting-edge research by Volition.
Who are the presenters at the poster sessions?
Jake Micallef and Marie Piecyk are the key presenters for Volition's posters, sharing critical insights from their research.
What is the significance of the Nu.Q® H3K27Me3 biomarker?
This biomarker enhances prognostic evaluations for NSCLC, potentially guiding treatment decisions for better patient management.
